Business context and reporting period
This is Priveterra Acquisition Corp.’s unaudited Form 10-Q for the quarter ended March 31, 2023—not an operating-company report for AEON Biopharma. Priveterra was a blank-check company pursuing a merger with AEON; it had not begun operations or generated operating revenue. The proposed transaction would make AEON a wholly owned subsidiary and rename the combined company AEON Biopharma, Inc. The filing describes an implied AEON equity value of $165 million, with 809,000 shares of merger consideration held back for certain convertible notes. The merger had not closed as of the report.
Financial results and liquidity
- Revenue: None. Priveterra’s income was non-operating, principally trust-account interest and changes in warrant fair value.
- Quarterly result: Net loss of $388,515, versus net income of $2.77 million in Q1 2022. Operating costs were $1.74 million, compared with $389,073. Q1 2023 included $1.70 million of trust interest, a $142,852 warrant fair-value loss, a $200,087 gain from forgiveness of an underwriting fee, and a $404,634 income-tax provision. No operating margin is meaningful for this pre-combination SPAC.
- Cash flow: Operating cash use was $623,931, versus $411,669 in Q1 2022. Cash at quarter-end was $457,085, up from $67,909 at year-end. Investing cash inflow of $260.0 million and financing cash outflow of $259.0 million largely reflected trust withdrawals and share redemptions.
- Trust and redemptions: Trust assets were $21.07 million at March 31, down from $279.38 million at December 31, 2022. At the February special meeting, holders redeemed 25,597,728 shares for $258,999,909; 2,002,272 redeemable public shares remained.
- Liabilities and capital: Total liabilities were $7.94 million, including $5.87 million current liabilities, $812,611 of warrant liabilities, and $1.26 million of deferred underwriting commission. Current liabilities included a $150,000 related-party note and a $424,059 excise-tax liability. Stockholders’ deficit was $7.32 million. The company reported a $5.25 million working-capital deficit, excluding taxes payable funded by trust earnings.
Material changes versus the prior comparable period
Results shifted from Q1 2022 income to a Q1 2023 loss, as higher operating costs, warrant remeasurement, and income taxes outweighed trust interest and the underwriting-fee forgiveness gain. The company also recorded a $1.70 million increase in trust interest versus $129,586 in Q1 2022. A large February redemption reduced trust assets and redeemable shares substantially. Separately, an underwriter waived $4.64 million of deferred fees in January; $1.26 million remained payable at quarter-end.
Outlook, risks, contingencies, and unusual items
- Combination deadline and going concern: Following a February stockholder vote, the deadline to complete a business combination was extended to August 11, 2023. Management stated that limited liquidity and the possibility of mandatory liquidation raise substantial doubt about the company’s ability to continue as a going concern. It intended to complete the merger before the deadline; no liquidation adjustments were recorded.
- Funding: The filing notes January interim-financing letter agreements with certain investors for an aggregate $20 million, but does not clearly establish the amount funded or available at March 31. Subsequent to quarter-end, on April 27, the sponsor provided for borrowing of up to $1 million under a non-interest-bearing unsecured note, payable upon the business combination.
- Legal and tax exposure: A purported stockholder sued in January, alleging omissions in the merger registration statement; other stockholders sent similar demand letters. The company recorded $424,059 of excise-tax liability related to redemptions, subject to potential offsets from same-year share issuances. The filing says the liability would not be due if the company liquidated before December 31, 2023, while also noting uncertainty in how the excise tax applies to SPAC transactions and liquidation.
- Controls: Management concluded disclosure controls were ineffective due to a material weakness in accounting for the extinguishment of a significant contingent obligation. It described remediation steps and stated that additional analysis was performed for the financial statements.
- Other uncertainties: The filing cites possible effects from COVID-19 and the war in Ukraine but says impacts were not readily determinable. No financial guidance is provided.
Important facts for investors to verify
- Whether the AEON merger closed by the August 11, 2023 deadline, and the final transaction terms, financing, and dilution after redemptions.
- Whether the stated $20 million interim financing was funded and what cash was available to the combined company.
- The company’s remaining liabilities and trust-account proceeds available at transaction closing, including deferred underwriting fees and any excise tax.
- The status and potential cost of the stockholder lawsuit and demand letters, and whether the material weakness was remediated.
- The final treatment of AEON convertible notes and the 809,000-share holdback described in the merger agreement.